Skip to main content

Advertisement

SpringerLink
Log in

Everolimus: A Guide to Its Use in Liver Transplantation

  • Adis Drug Clinical Q&A
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The mammalian target of rapamycin inhibitor everolimus (Zortress®, Certican®) was recently approved in the USA and a number of EU countries for use in combination with a reduced dosage of tacrolimus and corticosteroids for the prophylaxis of organ rejection in adult liver transplant recipients. Compared with standard-exposure tacrolimus, early use of everolimus plus a reduced dosage of tacrolimus did not compromise efficacy in liver transplant recipients. In addition, significantly better renal function with everolimus plus reduced-exposure tacrolimus than with standard-exposure tacrolimus was seen from 6 weeks post-transplant onwards. Everolimus plus reduced-exposure tacrolimus has an acceptable tolerability profile in liver transplant recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Meier-Kriesche H-U, Li S, Gruessner RWG, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006;6(5 Pt 2):1111–31.

    Article  PubMed  CAS  Google Scholar 

  2. McGuire BM, Rosenthal P, Brown CC, et al. Long-term management of the liver transplant patient: recommendations for the primary care doctor. Am J Transplant. 2009;9(9):1988–2003.

    Article  PubMed  CAS  Google Scholar 

  3. Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997;64(1):32–5.

    Article  PubMed  CAS  Google Scholar 

  4. Novartis. Zortress® (everolimus) tablets for oral use: US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021560s006lbl.pdf. Accessed 8 Mar 2013.

  5. Lakemedelsverket. Certican (everolimus) tablets: Swedish summary of product characteristics. 2012. http://www.lakemedelsverket.se/SPC_PIL/Pdf/enhumspc/Certican%20tablet%20ENG%20.doc. Accessed 8 Mar 2013.

  6. Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs. 2006;66(4):547–70.

    Article  PubMed  CAS  Google Scholar 

  7. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42.

    Article  PubMed  CAS  Google Scholar 

  8. Schuurman H-J, Ringers J, Schuler W, et al. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation. 2000;69(5):737–42.

    Article  PubMed  CAS  Google Scholar 

  9. Hausen B, Boeke K, Berry GJ, et al. Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation. 1999;67(7):956–62.

    Article  PubMed  CAS  Google Scholar 

  10. Hausen B, Ikonen T, Briffa N, et al. Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation. 2000;69(1):76–86.

    Article  PubMed  CAS  Google Scholar 

  11. De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15(10):1262–9.

    Article  PubMed  Google Scholar 

  12. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation: PROTECT. Am J Transplant. 2012;12(7):1855–65.

    Article  PubMed  CAS  Google Scholar 

  13. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10(10):2252–62.

    Article  PubMed  CAS  Google Scholar 

  14. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12(11):3008–20.

    Article  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Gillian M. Keating & Katherine A. Lyseng-Williamson

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Additional information

The manuscript was reviewed by: F. Saliba, Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejif, France.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M., Lyseng-Williamson, K.A. Everolimus: A Guide to Its Use in Liver Transplantation. BioDrugs 27, 407–411 (2013). https://doi.org/10.1007/s40259-013-0041-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-013-0041-6

Keywords

Search

Navigation